MedTrace Logo

Diosmin Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome

NCT02134249 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2016-02-02

No results posted yet for this study

Summary

The purpose of this study is to compare the effect of oral Diosmin to oral Cabergoline in the prevention of ovarian hyperstimulation syndrome (OHSS) in high-risk women underwent intracytoplasmic sperm injection (ICSI).

Conditions

Interventions

DRUG

Diosmin

2 tab / 8 hs Diosmin ( 500mg) will be given at day of HCG injection and for14 days

DRUG

Cabergoline

1 tab/day Cabergoline( 0.5 mg) will be given at day of HCG injection and for 8 days

Sponsors & Collaborators

  • Benha University

    lead OTHER

Principal Investigators

  • khalid mohamed, MD · Department of Obstetrics and Gynecology, Benha University Hospital

  • ahmed samy, MD · Department of Obstetrics and Gynecology, Benha University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
23 Years
Max Age
48 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2015-09-30
Completion
2015-10-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02134249 on ClinicalTrials.gov